Notícias

Two class action lawsuits claim Hims & Hers Health did not adequately safeguard sensitive customer data during recent data breaches. The suits allege delayed notification to affected customers and increased risk of identity theft, and they seek damages plus stronger data security oversight. These cases introduce fresh legal and reputational questions for NYSE:HIMS that have not been widely covered so far. For investors watching NYSE:HIMS, this legal development adds a new angle to a stock...

Hims & Hers and Teladoc Health are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.

HIMS broadens digital-first care with Novo Nordisk GLP-1 access, new cancer detection and Labs tools, along with expansion into Canada and Europe.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 4% in the afternoon session after the stock's momentum weakened as Amazon.com entered the weight management market through its One Medical platform.

Hims & Hers Health (NYSE:HIMS) has nominated Kofi Amoo-Gottfried as a new independent director to its board. Amoo-Gottfried brings senior marketing experience from roles at DoorDash and Meta. The company is also reducing the overall size of its board as part of this change. Hims & Hers Health operates in telehealth and wellness, with a model built around digital customer acquisition, recurring subscriptions and branded experiences. As virtual care, online pharmacies and direct to consumer...

A confluence of safety concerns and underwhelming clinical data sent Erasca stock into a historic tailspin on Tuesday. Erasca late Monday reported positive Phase 1 trial results for ERAS-0015, a therapeutic drug candidate tailored to patients with lung and pancreatic cancer. Investors quickly drew parallels to daraxonrasib, the high-profile lead asset from Revolution Medicines Daraxonrasib has been on the receiving end of a storm of media coverage following an endorsement from former Nebraska Sen. Ben Sasse.

OMCL vs. HIMS: Which Stock Is the Better Value Option?